Akebia Therapeutics (STU:AX9) Institutional Ownership: 25.19% (As of Jul. 12, 2026)


STU:AX9 Akebia Therapeutics Inc STU:AX9
50 GF Score
Price €1.22
GF Value €1.10
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Akebia Therapeutics Institutional Ownership?

Akebia Therapeutics STU:AX9 -1.98% 50 Institutional Ownership is 25.19% as of Jul. 12, 2026. GuruFocus rates STU:AX9 with a GF Score™ of 50/100 and a GF Value™ of €1.10 (Fairly Valued). The stock has 5 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Akebia Therapeutics's institutional ownership is 25.19%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Akebia Therapeutics's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Akebia Therapeutics's Float Percentage Of Total Shares Outstanding is 98.53%.

Akebia Therapeutics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Akebia Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Akebia Therapeutics Institutional Ownership Chart

Akebia Therapeutics Historical Data

The historical data trend for Akebia Therapeutics can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 30.16 30.16 29.75 30.55 30.86 30.30 26.77 26.07 27.02 25.19
STU:AX9
50GF Score
Akebia Therapeutics Inc STU:AX9
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Akebia Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 25.19% mean?
Akebia Therapeutics (STU:AX9) has a Institutional Ownership of 25.19% as of Jul. 12, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Akebia Therapeutics and its competitors.
Is Akebia Therapeutics' Institutional Ownership too high?
Akebia Therapeutics' current Institutional Ownership is 25.19%. Overall, Akebia Therapeutics has a GF Score™ of 50/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Akebia Therapeutics' Institutional Ownership compare to TKNO and ORGO?
Akebia Therapeutics' Institutional Ownership of 25.19% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Drug Manufacturers company?
A good Institutional Ownership depends on the Drug Manufacturers industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Akebia Therapeutics and its competitors. Akebia Therapeutics's current Institutional Ownership is 25.19%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akebia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Akebia Therapeutics (STU:AX9) is currently considered Fairly Valued. The stock's GF Value™ is €1.10, compared to a current price of €1.22 — trading 10.5% above its estimated fair value. The current Institutional Ownership is 25.19%. Akebia Therapeutics' overall GF Score™ is 50/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Akebia Therapeutics (STU:AX9), the current Institutional Ownership is 25.19% as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Akebia Therapeutics (STU:AX9) Overvalued in 2026?

Based on GuruFocus' analysis, Akebia Therapeutics stock appears to be overvalued. The current stock price of €1.22 is trading 10.5% above its estimated GF Value™ of €1.10. GuruFocus considers Akebia Therapeutics to be Fairly Valued.

Key valuation signals for STU:AX9:

  • Institutional Ownership: 25.19%
  • GF Value™: €1.10 vs. price of €1.22 (10.5% above fair value)
  • GF Score™: 50/100 with 5 warning signs

No single metric tells the full story. See the STU:AX9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Akebia Therapeutics Business Description

Other Exchanges AKBA:USA
Address 245 First Street, Suite 1400, Cambridge, MA, USA, 02142
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
50GF Score

Get the complete analysis for STU:AX9

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.22
Price
€1.10
GF Value